Allarity Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
ALLR$0.91-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(U.S. dollars in thousands, except for share and per share data*)
| 2023 | 2022 | |
|---|---|---|
| Operating expenses: | ||
| Research and development | $7,103 | $6,930 |
| Impairment of intangible assets | — | 17,571 |
| General and administrative | 10,026 | 9,962 |
| Total operating expenses | 17,129 | 34,463 |
| Loss from operations | (17,129) | (34,463) |
| Other income (expenses) | ||
| Income from the sale of IP | — | 1,780 |
| Interest income | 22 | 30 |
| Interest expenses | (498) | (223) |
| Loss on investment | — | (115) |
| Foreign exchange gains (losses) | 133 | (913) |
| Fair value of inducement warrants | (4,189) | — |
| Loss on modification of warrants | (591) | — |
| Change in fair value adjustment of warrant derivative liabilities | 10,434 | 17,125 |
| Penalty on Series A Preferred stock liability | — | (800) |
| Net other income, net | 5,311 | 16,884 |
| Net loss before tax recovery (expense) | (11,818) | (17,579) |
| Deferred income tax (expense) benefit | (83) | 1,521 |
| Net loss | (11,901) | (16,058) |
| Cash payable on converted Series A Preferred Stock | — | (3,421) |
| Deemed dividends on Series A Preferred Stock | (8,392) | — |
| Deemed dividend of on Series C Preferred Stock | (123) | (1,572) |
| Net loss attributable to common stockholders | $(20,416) | $(21,051) |
| Basic and diluted net loss per common stock | $(10.26) | $(3,093.42) |
| Weighted average number of common stock outstanding, basic and diluted | 1,990,748 | 6,805 |
| Other comprehensive loss, net of tax: | ||
| Net loss | $(11,901) | $(16,058) |
| Change in cumulative translation adjustment | 310 | (121) |
| Comprehensive loss attributable to common stockholders | $(11,591) | $(16,179) |
| * | All common share data has been retroactively adjusted to effect reverse stock splits in 2023 (see Notes 1 and 10.) |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.